Patient P-03323
Therapy response
Stable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S14
- Day 64 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 70 GI-04 recommended — GI Support Protocol GI-04
- Day 71 Patient accepted — Started GI-04 in the companion
- Day 79 GI symptom burden −20% vs expected — GI Support Protocol GI-04
- Day 81 ME-01 recommended — Monitoring Escalation ME-01
- Day 82 Patient accepted — Started ME-01 in the companion
- Day 85 Tolerance state changed — Unstable → Improving
- Day 85 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 64.
Primary contributors, last 14 days
- GI instability+18
- Inflammatory activity+11
- Nutritional resilience-7
- Toxicity+3
What helped?
- GI Support Protocol GI-04Day 70Result: symptom burden −20%
- Monitoring Escalation ME-01Day 81Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
79%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 88% showed improvement
- median effect visible after 6 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 62 and rising
- Inflammatory signalling ↑25
- BloodInflammatory load index 58
- Autonomic recovery ↓25
- WearableResting HR 73 bpm
- Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑20
- BloodToxicity index 49
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 3 · butyrate capacity 46/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 49 ms
- Sleep
- 6.4 h
- Steps
- 6,590
- Resting HR
- 73 bpm
Daily log: GI score 62, nutritional resilience 41, adherence 46.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03037 | 57% | S14 | NP-02 | improved | 43 |
| P-03049 | 51% | S14 | GI-04 | improved | 49 |
| P-03345 | 50% | S14 | SC-12 | improved | 56 |
| P-03293 | 49% | S14 | GI-04 | no change | 41 |
| P-03390 | 47% | S14 | ME-01 | improved | 41 |
| P-03460 | 46% | S11 | SC-12 | improved | 46 |
| P-03146 | 45% | S14 | GI-04 | improved | 53 |
| P-03413 | 45% | S14 | ME-01 | improved | 48 |
| P-03070 | 44% | S14 | GI-04 | improved | 51 |
| P-03341 | 44% | S14 | NP-02 | improved | 49 |
| P-03430 | 44% | S14 | SC-12 | improved | 45 |
| P-03123 | 43% | S14 | GI-04 | improved | 50 |